2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. STK33

STK33

Serine/threonine kinase 33

Serine/Threonine Kinase 33 (STK33) plays a pivotal role in cancer cell proliferation and metastasis by phosphorylating serine and threonine residues on proteins, thereby regulating crucial cellular processes such as signal transduction, DNA replication, cell differentiation, proliferation, apoptosis, and tumor development. STK33 is overexpressed in various cancers, including pancreatic, lung, and liver cancers, compared to non-cancerous tissues. Notably, STK33 activates the PI3K/Akt/mTOR signaling pathway in gastric cancer, promoting metastasis. Additionally, the STK33/ERK2 signaling pathway contributes to the tumorigenesis of colorectal cancer by phosphorylating ERK2, enhancing its activity and promoting cancer progression. STK33's involvement in cancer development underscores its importance in oncology research.[1][2].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13495
    ML281
    		Inhibitor 99.91%
    ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM.
    ML281
  • HY-114331
    DLK-IN-1
    		Inhibitor 99.18%
    DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research.
    DLK-IN-1
  • HY-162565
    CDD-2807
    		Inhibitor 99.52%
    CDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive.
    CDD-2807
  • HY-176885
    CDD-2211
    		Inhibitor
    CDD-2211 is a STK33 inhibitor, with a Kd of 0.018 nM and an IC50 of 5 nM. CDD-2211 has relatively weak inhibitory effects on off-target kinases, with IC50 values of 115 nM for CLK1, 48 nM for CLK2, 187 nM for CLK4, and 78 nM for RET. CDD-2211 can be used for the study of contraception.
    CDD-2211
  • HY-13498
    BRD-8899
    		Inhibitor
    BRD-8899 is a STK33 inhibitor, with an IC50 of 11 nM.
    BRD-8899
  • HY-176884
    CDD-2110
    		Inhibitor
    CDD-2210 is a STK33 inhibitor, with a Kd of 0.1 nM and an IC50 of 38 nM. CDD-2210 has relatively weak inhibitory effects on off-target kinases, with IC50 values of 1209 nM for CLK1, 917 nM for CLK2, 544 nM for CLK4, and 746 nM for RET. CDD-2210 can be used for the study of contraception.
    CDD-2110
  • HY-176885A
    CDD-2212
    		Inhibitor
    CDD-2212 is a STK33 inhibitor, with a Kd of 1.9 nM and an IC50 of 999 nM. CDD-2212 has relatively weak inhibitory effects on off-target kinases, with IC50 values of 3223 nM for CLK1, 1555 nM for CLK2, 5884 nM for CLK4, and 1093 nM for RET. CDD-2212 can be used for the study of contraception.
    CDD-2212
  • HY-13497
    STK33-IN-1
    		Inhibitor
    STK33-IN-1 (compound 1) is a STK33 inhibitor, with an IC50 of 7 nM.
    STK33-IN-1
Cat. No. Product Name / Synonyms Application Reactivity